In cooperation with the Food and Drug Administrations (FDA) Office of Oncology Drug Products, and as a service to our members, ASCO periodically distributes, via e-mail, notification of recent FDA approvals and other important FDA actions pertaining to therapies for cancer patients. These alerts help the FDA to inform oncologists and other professionals in oncology-related fields of recent approvals and other important FDA actions, in a timely manner. Included in each FDA e-mail is a link to the product label, which provides relevant clinical information on the indication, contraindications, dosing and safety.
Please note that in sending this information, ASCO does not endorse any product or therapy, and does not take any position on the safety or efficacy of the product or therapy described.
For a complete listing of FDA-approved oncology drugs, visit the FDA Approved Oncology Drug website.
|
